Interní Med. 2012; 14(11): 443-446

Sjögrenův syndrom.

MUDr.Radka Svobodová
Revmatologický ústav, Praha

Systemic connective tissue diseases and their complications

Systemic connective tissue diseases are chronic conditions that, in addition to the musculoskeletal system (joints, tendons, and muscles),

can affect numerous other organs, including the skin, heart, lungs, kidneys, nervous system, eyes, and digestive tract. They include

rheumatoid arthritis, systemic lupus erythematosus, systemic scleroderma, myositis, Sjögren’s syndrome, vasculitides and others. In the

early period of the disease, complications most often arise that are related to the degree of organ involvement; in the late period, they

develop as a result of long-term organ damage or due to adverse effects of long-term immunosuppressive therapy. These complications

are mostly very severe, life-threatening conditions with a poor prognosis (sepsis, pulmonary and renal involvement).

Sjögren’s syndrome.

Keywords: systemic connective tissue diseases, rheumatoid arthritis, systemic lupus erythematosus, systemic scleroderma, myositis,

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svobodová R. Sjögrenův syndrom. Interní Med. 2012;14(11):443-446.
Download citation

References

  1. Turesson C, O´Fallon WM, Crowson CS, et al. Occurrence of extra-articular disease manifestations is associated with excess mortality in a population-based cohort of patients with rheumatoid arthritis. J Rheumatol 2002; 29: 62-67. Go to PubMed...
  2. Turesson C, O´Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatiod arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62: 722-727. Go to original source... Go to PubMed...
  3. Kerstens PJSM, Boerbooms AMT, Jeurissen MEC, et al. Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten CASE. J Rheumatol 1992; 19: 867-871. Go to PubMed...
  4. Vencovský J, et al. Bezpečnost biologické léčby - doporučení České revmatologické společnosti. Čes Revmatol 2009; 17(3): 146-160.
  5. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722-732. Go to original source... Go to PubMed...
  6. Le Guern V, Mouthon L. Sjögren ´s syndrome and non-Hodgkin´s lymfoma: from pathophysiology to treatment. Presse Med 2011; 40: 1113-1119. Go to original source... Go to PubMed...
  7. Martinez-Martinez MU, Abud-Mendoza C. Recurrent diffuse alveolar heamorrhage in a patient with systemic lupus erythematosus. long term benefit of Rituximab. Lupus 2012; Mar 29. [Epub ahead of print]. Go to original source... Go to PubMed...
  8. Calderaro DC, Ferreira GA. Presentation and prognosis of shrinking lung syndrome in systemic lupus erythematosus: report of four cases. Rheumatol Int 2012; 32: 1391-1396. Go to original source... Go to PubMed...
  9. Pavelka K., Gatterová J., Sainerová A. Mnohočetné osteonekrózy u nemocné se systémovým onemocněním pojiva po léčbě kortikosteroidy. Čes Revmatol 1999; 3: 142-145.
  10. Formiga F, Moga I, nolla JM et al. loss of bone mineral density in premenopausalwomen with SLE. Ann Rheum Dis 1995; 54: 274-276. Go to original source... Go to PubMed...
  11. Kahl LE. herpes zoster infections in SLE: risk factor and outcome. J Rheumatol 1994; 231: 84-86.
  12. Sharam F, Akbarian M, Davatchi F. Salmonella infection in SLE. Lupus 1993; 2: 55-59. Go to original source... Go to PubMed...
  13. Li J, Huang XM, Fang WG, Zeng XJ. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin rheumatol 2006; 12: 114-117. Go to original source... Go to PubMed...
  14. Gyger G, Baron M. Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep 2012; 14: 22-29. Go to original source... Go to PubMed...
  15. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-3530. Go to original source... Go to PubMed...
  16. Zbiti N, Houssaini TS, Benkirane A, et al. Sclerodermic renal crisis: case report. Nephrol ther 2010; 6: 606-609. Go to original source... Go to PubMed...
  17. Fathi M, Lundberg IE, Tornling G. Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med 2007; 28: 451-458. Go to original source... Go to PubMed...
  18. Marie I, Hachulla E, Chérin P, et al. Opportunistic Infections in Polymyositis and Dermatomyositis. Arthritis and Rheumatism 2005; 53: 155-156. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.